{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:45:25Z","timestamp":1792079125624,"version":"4.4.0"},"reference-count":106,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec id=\"ab-crv260002-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The treatment of older adults with chemotherapy for early-stage breast cancer involves a complex decision-making process that weighs the competing risks of disease recurrence against the potential harms of treatment. While older adults continue to be underrepresented in therapeutic clinical trials, there is a growing body of evidence to support optimal management of each subtype of early-stage breast cancer, including novel strategies like adjuvant cyclin-dependent kinase 4\/6 inhibitors in hormone receptor\u2013positive disease, and the neoadjuvant use of pembrolizumab in triple-negative breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv260002-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>The available evidence to support the systemic management of early-stage breast cancer in older adults with consideration of the data gaps for cytotoxic chemotherapy, de-escalated regimens, and targeted therapies is reviewed, and tools to optimize decision-making and supportive care for older adults with early breast cancer are presented. Clinicians should aim to avoid overtreatment when available evidence suggests a less intensive approach may suffice for a lower-risk cancer, and\/or the patient is at high risk of serious toxic effects from chemotherapy treatment. On the other hand, undertreatment without consideration of the potential downsides may increase breast cancer\u2013related mortality in older patients with higher-risk cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv260002-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This review will help clinicians best use the available data and decision-making tools to support best practice for treating older adults with early-stage breast cancer and will highlight ongoing clinical trials aimed at optimizing medical care for this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.3121","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:30:34Z","timestamp":1787844634000},"page":"1145","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Claire E.","family":"Smith","sequence":"first","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Sammons","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Minami","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Now with Department of Surgery, Cumming School of Medicine, University of Calgary, Alberta, Canada"},{"name":"Now with Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina S.","family":"Sedrak","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Magnuson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy T.","family":"Hshieh","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Smith","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ruderman","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Bak","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"crv260002r1","first-page":"477","article-title":"Breast cancer statistics 2024.","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"crv260002r2","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1002\/cncr.31308","article-title":"Breast cancer-specific survival by age: worse outcomes for the oldest patients.","volume":"124","author":"Freedman","year":"2018","journal-title":"Cancer"},{"issue":"9","key":"crv260002r3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.293.9.1073","article-title":"Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.","volume":"293","author":"Muss","year":"2005","journal-title":"JAMA"},{"issue":"18","key":"crv260002r4","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2005.02.3028","article-title":"Use and outcomes of adjuvant chemotherapy in older women with breast cancer.","volume":"24","author":"Giordano","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"crv260002r5","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1200\/JCO.2005.03.6053","article-title":"Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.","volume":"24","author":"Elkin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"24","key":"crv260002r6","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","article-title":"Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.","volume":"25","author":"Muss","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"crv260002r7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s11764-024-01594-3","article-title":"Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study.","volume":"18","author":"Sedrak","year":"2024","journal-title":"J Cancer Surviv"},{"issue":"2","key":"crv260002r8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1200\/JCO.22.01440","article-title":"Low-intensity adjuvant chemotherapy for breast cancer in older women: results from the prospective multicenter HOPE trial.","volume":"41","author":"Sedrak","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"crv260002r9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer.","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"crv260002r10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jgo.2021.07.008","article-title":"Disparities in older adult accrual to cancer trials: analysis from the Alliance for Clinical Trials in Oncology (A151736).","volume":"13","author":"Van der Walde","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"22","key":"crv260002r11","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1200\/JCO.19.02809","article-title":"Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review.","volume":"38","author":"DuMontier","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"crv260002r13","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1200\/JCO.2017.72.8170","article-title":"Time to stop saying geriatric assessment is too time consuming.","volume":"35","author":"Hamaker","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"crv260002r14","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study.","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"10314","key":"crv260002r15","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"crv260002r16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1200\/JCO.2009.23.5440","article-title":"Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up.","volume":"28","author":"Clough-Gorr","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv260002r17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","article-title":"Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program.","volume":"6","author":"Mohile","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"crv260002r18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jgo.2018.03.014","article-title":"The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients \u2014 a systematic review.","volume":"9","author":"Hamaker","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"crv260002r19","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","article-title":"Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.","volume":"34","author":"Corre","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"crv260002r20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/bjc.2015.120","article-title":"The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people.","volume":"112","author":"Kalsi","year":"2015","journal-title":"Br J Cancer"},{"issue":"s4","key":"crv260002r21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/ajco.12799","article-title":"Assessing treatment tolerability after geriatric assessment in the senior oncology clinic at the Gold Coast University Hospital.","volume":"13","author":"Fletcher","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"crv260002r22","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool.","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"10","key":"crv260002r23","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","article-title":"Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review.","volume":"13","author":"Hamaker","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"crv260002r24","doi-asserted-by":"publisher","first-page":"M750","DOI":"10.1093\/gerona\/55.12.M750","article-title":"Identifying a short functional disability screen for older persons.","volume":"55","author":"Saliba","year":"2000","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"crv260002r26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047376","article-title":"Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study.","volume":"11","author":"Ostwal","year":"2021","journal-title":"BMJ Open"},{"issue":"20","key":"crv260002r27","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a prediction tool for chemotherapy toxicity in older adults with cancer.","volume":"34","author":"Hurria","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv260002r29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/jnci\/djad029","article-title":"Toxicity risk score and clinical decline after adjuvant chemotherapy in older breast cancer survivors.","volume":"115","author":"Ji","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"crv260002r31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/bjc.2015.466","article-title":"Validity of the online PREDICT tool in older patients with breast cancer: a population-based study.","volume":"114","author":"de Glas","year":"2016","journal-title":"Br J Cancer"},{"issue":"6","key":"crv260002r33","doi-asserted-by":"publisher","DOI":"10.3310\/XZOE2552","article-title":"Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT.","volume":"10","author":"Wyld","year":"2022","journal-title":"Programme Grants for Applied Research"},{"issue":"6","key":"crv260002r35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.6004\/jnccn.2023.7015","article-title":"Predicting all-cause mortality in women with and without breast cancer using the Schonberg index: a Women\u2019s Health Initiative study.","volume":"21","author":"Nelson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"crv260002r36","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.20.02063","article-title":"Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer.","volume":"39","author":"Magnuson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"crv260002r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric Assessment-Driven Intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial.","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"crv260002r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.26076","article-title":"Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial.","volume":"7","author":"Ostwal","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"crv260002r39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/107327480701400105","article-title":"Pharmacokinetics of chemotherapy in the older patient.","volume":"14","author":"Hurria","year":"2007","journal-title":"Cancer Control"},{"issue":"20 Pt 1","key":"crv260002r40","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-06-0200","article-title":"Pharmacokinetics and toxicity of weekly docetaxel in older patients.","volume":"12","author":"Hurria","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"crv260002r41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2014-0202","article-title":"Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age.","volume":"20","author":"Hurria","year":"2015","journal-title":"Oncologist"},{"issue":"12","key":"crv260002r42","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1200\/JCO.2005.03.9289","article-title":"Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).","volume":"24","author":"Lichtman","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"crv260002r43","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"crv260002r44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"issue":"13","key":"crv260002r45","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/cncr.33489","article-title":"Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer\u2014a National Cancer Database analysis.","volume":"127","author":"Tamirisa","year":"2021","journal-title":"Cancer"},{"issue":"25","key":"crv260002r46","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"crv260002r47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"crv260002r48","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71386","article-title":"Oncotype Dx breast cancer assay in older patients: a real life cohort.","volume":"14","author":"Grosnon","year":"2025","journal-title":"Cancer Med"},{"issue":"10502","key":"crv260002r49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(25)00832-3","article-title":"Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.","volume":"406","author":"Brain","year":"2025","journal-title":"Lancet"},{"issue":"16","key":"crv260002r50","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.2026.44.16_suppl.500","article-title":"First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.","volume":"44","author":"Stein","year":"2026","journal-title":"J Clin Oncol"},{"issue":"20","key":"crv260002r51","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa0810266","article-title":"Adjuvant chemotherapy in older women with early-stage breast cancer.","volume":"360","author":"Muss","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"crv260002r52","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1200\/JCO.2010.29.9859","article-title":"Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.","volume":"29","author":"Kornblith","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"crv260002r53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/annonc\/mdu564","article-title":"Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.","volume":"26","author":"Perrone","year":"2015","journal-title":"Ann Oncol"},{"issue":"10384","key":"crv260002r54","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100?000 women from 86 randomised trials.","volume":"401","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk","year":"2023","journal-title":"Lancet"},{"issue":"25","key":"crv260002r55","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv260002r56","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-016-4051-1","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).","volume":"161","author":"Freedman","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"crv260002r57","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.2013.49.3676","article-title":"Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.","volume":"32","author":"Barcenas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"crv260002r58","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1200\/jco.2004.22.90140.595","article-title":"Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: a non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT).","volume":"22","author":"Rea","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"crv260002r59","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1001\/jamaoncol.2015.3062","article-title":"Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis.","volume":"1","author":"Fujii","year":"2015","journal-title":"JAMA Oncol"},{"key":"crv260002r60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2018.05.017","article-title":"Palbociclib plus endocrine therapy in older women with HR+\/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.","volume":"101","author":"Rugo","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"crv260002r61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/10781552211050106","article-title":"A deep dive into CDK4\/6 inhibitors: evaluating real world toxicities and treatment paradigms in the elderly population.","volume":"29","author":"Olazagasti","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"crv260002r62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16","key":"crv260002r63","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1200\/JCO.2023.41.16_suppl.501","article-title":"Efficacy and safety results by age in monarchE: adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).","volume":"41","author":"Hamilton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"crv260002r64","doi-asserted-by":"publisher","first-page":"S313","DOI":"10.1016\/j.annonc.2024.08.183","article-title":"240P Efficacy and safety of ribociclib (RIB)?+?nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+\/HER2- early breast cancer (EBC) in NATALEE.","volume":"35","author":"Untch","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"crv260002r65","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","article-title":"Ribociclib plus endocrine therapy in hormone receptor-positive\/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial.","volume":"11","author":"Fasching","year":"2025","journal-title":"JAMA Oncol"},{"issue":"16","key":"crv260002r66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.2025.43.16_suppl.517","article-title":"The TRADE study: a phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+\/HER2- breast cancer.","volume":"43","author":"Mayer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv260002r67","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03).","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"crv260002r68","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1634\/theoncologist.2014-0184","article-title":"Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.","volume":"19","author":"Jenkins","year":"2014","journal-title":"Oncologist"},{"issue":"16","key":"crv260002r69","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.2023.41.16_suppl.517","article-title":"Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.","volume":"41","author":"Waks","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"crv260002r70","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1200\/JCO.2013.53.1608","article-title":"Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.","volume":"32","author":"Vaz-Luis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv260002r71","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"31","key":"crv260002r72","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.02170","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2-positive breast cancer: 5-year results and correlative analyses from ATEMPT.","volume":"42","author":"Tarantino","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"crv260002r73","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): a randomized clinical trial.","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv260002r74","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41523-022-00495-x","article-title":"Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel\/trastuzumab (ATEMPT).","volume":"8","author":"Sella","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"4_Supplement","key":"crv260002r75","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-PS3-11-04","article-title":"Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with HER2+ breast cancer \u2014 results from the ATOP study.","volume":"32","author":"Freedman","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"32","key":"crv260002r76","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.20.00184","article-title":"Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients.","volume":"38","author":"Sawaki","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"crv260002r78","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"crv260002r79","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","article-title":"De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.","volume":"26","author":"Chen","year":"2025","journal-title":"Lancet Oncol"},{"issue":"17","key":"crv260002r80","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1200\/JCO-25-02176","article-title":"Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2-positive breast cancer: the randomized noninferiority phase III neoCARHP Trial.","volume":"44","author":"Gao","year":"2026","journal-title":"J Clin Oncol"},{"issue":"17","key":"crv260002r81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA500","article-title":"De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): a multicentre, open-label, randomised, phase 3 trial.","volume":"43","author":"Gao","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"crv260002r82","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1200\/JCO.2025.43.16_suppl.501","article-title":"Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181\/CompassHER2 pCR trial.","volume":"43","author":"Tung","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv260002r83","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"issue":"9","key":"crv260002r84","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer.","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"issue":"7","key":"crv260002r85","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"crv260002r86","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.2023.41.16_suppl.1006","article-title":"An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03.","volume":"41","author":"Krop","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv260002r87","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"crv260002r88","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaoncol.2023.0646","article-title":"Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive\/ERBB2-positive early breast cancer: the neoadjuvant WSG-TP-II randomized clinical trial.","volume":"9","author":"Gluz","year":"2023","journal-title":"JAMA Oncol"},{"key":"crv260002r89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01047","article-title":"Survival analysis of the WSG TP-II trial: neoadjuvant trastuzumab and pertuzumab plus endocrine therapy versus chemotherapy in hormone receptor-positive\/human epidermal growth factor receptor 2-positive early breast cancer.","author":"Gluz","year":"2026","journal-title":"J Clin Oncol"},{"issue":"22","key":"crv260002r90","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1200\/JCO.22.01816","article-title":"De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+\/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial.","volume":"41","author":"Harbeck","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv260002r91","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"crv260002r92","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"crv260002r93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13058-021-01392-0","article-title":"Molecular analyses of triple-negative breast cancer in the young and elderly.","volume":"23","author":"Aine","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"14","key":"crv260002r94","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1002\/cncr.32922","article-title":"Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.","volume":"126","author":"Ma","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"crv260002r95","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/oncolo\/oyae064","article-title":"Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis.","volume":"29","author":"LeVee","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"crv260002r96","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.3390\/curroncol28040215","article-title":"Cancer-specific outcomes in the elderly with triple-negative breast cancer: a systematic review.","volume":"28","author":"Yoon","year":"2021","journal-title":"Curr Oncol"},{"issue":"12","key":"crv260002r97","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S1470-2045(20)30538-6","article-title":"Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.","volume":"21","author":"Crozier","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"crv260002r98","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jgo.2020.09.004","article-title":"Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer.","volume":"12","author":"Valachis","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"crv260002r99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41523-024-00634-6","article-title":"Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer.","volume":"10","author":"Tarantino","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"crv260002r100","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","article-title":"Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial.","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"crv260002r101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2022.09.006","article-title":"\u2018ADVANCE\u2019 (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.","volume":"14","author":"Freedman","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"crv260002r102","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jamaoncol.2024.1917","article-title":"Tumor-infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy.","volume":"10","author":"Geurts","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"crv260002r103","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41523-026-00919-y","article-title":"Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real\/GBECAM-0123.","volume":"12","author":"Gouveia","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"crv260002r104","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107318","article-title":"Pembrolizumab as first-line treatment for advanced NSCLC in older adults: a phase II clinical trial evaluating geriatric and quality-of-life outcomes.","volume":"183","author":"Blanco","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"crv260002r105","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial.","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"crv260002r106","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10549-025-07637-2","article-title":"Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer.","volume":"211","author":"Sullivan","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"crv260002r12","unstructured":"Geriatric Assessment. Accessed December 28, 2025. https:\/\/mycarg.org\/pga-landing-page\/"},{"key":"crv260002r25","unstructured":"Cancer and Aging Research Group. Accessed March 11, 2026. https:\/\/mycarg.org\/resources-activities\/tools\/select-tool\/ctcl\/"},{"key":"crv260002r28","unstructured":"Cancer and Aging Research Group\u2013Breast Cancer. Accessed December 28, 2025. https:\/\/www.cancercalc.com\/carg_bc.php"},{"key":"crv260002r30","unstructured":"PREDICT. Accessed December 28, 2025. https:\/\/breast.v3.predict.cam\/tool"},{"key":"crv260002r32","unstructured":"Age Gap. Accessed December 28, 2025. https:\/\/agegap.shef.ac.uk\/"},{"key":"crv260002r34","unstructured":"Lee Schonberg Index. Accessed December 28, 2025. https:\/\/eprognosis.ucsf.edu\/leeschonberg.php"},{"key":"crv260002r77","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast cancer; version 3.2025. March 18, 2025. Accessed September 1, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2853305\/jamaoncology_smith_2026_rv_260002_1792007346.92111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:52Z","timestamp":1792076452000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2853305"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":106,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.3121","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}